JP2022510207A5 - - Google Patents
Info
- Publication number
- JP2022510207A5 JP2022510207A5 JP2021530163A JP2021530163A JP2022510207A5 JP 2022510207 A5 JP2022510207 A5 JP 2022510207A5 JP 2021530163 A JP2021530163 A JP 2021530163A JP 2021530163 A JP2021530163 A JP 2021530163A JP 2022510207 A5 JP2022510207 A5 JP 2022510207A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025018442A JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774278P | 2018-12-02 | 2018-12-02 | |
| US62/774,278 | 2018-12-02 | ||
| PCT/US2019/063024 WO2020117526A1 (en) | 2018-12-02 | 2019-11-25 | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018442A Division JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510207A JP2022510207A (ja) | 2022-01-26 |
| JPWO2020117526A5 JPWO2020117526A5 (https=) | 2022-12-12 |
| JP2022510207A5 true JP2022510207A5 (https=) | 2022-12-12 |
Family
ID=70974390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530163A Pending JP2022510207A (ja) | 2018-12-02 | 2019-11-25 | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
| JP2025018442A Pending JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025018442A Pending JP2025072543A (ja) | 2018-12-02 | 2025-02-06 | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12435123B2 (https=) |
| EP (1) | EP3891177A4 (https=) |
| JP (2) | JP2022510207A (https=) |
| KR (1) | KR102943217B1 (https=) |
| CN (1) | CN113166232A (https=) |
| AU (1) | AU2019392265A1 (https=) |
| BR (1) | BR112021010331A2 (https=) |
| CA (1) | CA3121128A1 (https=) |
| IL (1) | IL283607A (https=) |
| MX (1) | MX2021006194A (https=) |
| SG (1) | SG11202105480WA (https=) |
| WO (1) | WO2020117526A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021292695A1 (en) * | 2020-06-19 | 2023-02-02 | Fate Therapeutics, Inc. | Combining iPSC-derived effector cell types for immunotherapy use |
| CN114525255A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-11的多能干细胞衍生物及其应用 |
| CA3196549A1 (en) * | 2020-11-04 | 2022-05-12 | Bahram Valamehr | Engineered ipsc and immune effector cells for heterogenous tumor control |
| JP2023548467A (ja) * | 2020-11-04 | 2023-11-17 | フェイト セラピューティクス，インコーポレイティド | 操作されたｉＰＳＣ及び持続性免疫エフェクター細胞 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| CA3204417A1 (en) * | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| CN117615781A (zh) * | 2021-02-25 | 2024-02-27 | 克莱格医学有限公司 | Cd94工程化细胞及其组合物 |
| US20220333074A1 (en) * | 2021-04-07 | 2022-10-20 | Century Therapeutics, Inc. | Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells |
| JP2024522756A (ja) * | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| CN118284686A (zh) * | 2021-11-24 | 2024-07-02 | 杭州启函生物科技有限公司 | 用于基于细胞的免疫疗法的系统和方法 |
| EP4353741A1 (en) * | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| WO2024183750A1 (en) * | 2023-03-07 | 2024-09-12 | Qihan Hong Kong Limited | A novel immune cell and use thereof for treating diseases |
| WO2025189046A2 (en) * | 2024-03-06 | 2025-09-12 | The Johns Hopkins University | Pantigen specific cytokine receptor stimulation of immune cell function |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| JP5368301B2 (ja) | 2006-06-22 | 2013-12-18 | ノボ・ノルデイスク・エー／エス | 可溶性ヘテロ二量体レセプター及びその使用 |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| EP3549611B1 (en) | 2011-07-29 | 2021-06-30 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| EP3656864A1 (en) | 2014-02-14 | 2020-05-27 | Board of Regents, The University of Texas System | Chimeric antigen receptors and methods of making |
| SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| CN113699159A (zh) | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
| US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
| SG10202111851YA (en) | 2015-10-16 | 2021-12-30 | Fate Therapeutics Inc | Platform for the Induction & Maintenance of Ground State Pluripotency |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2019506143A (ja) | 2015-12-14 | 2019-03-07 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 治療用細胞の活性化及び排除のための二重コントロール |
| CA3010236A1 (en) * | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3083779A1 (en) | 2017-12-22 | 2019-06-27 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
-
2019
- 2019-11-25 KR KR1020217019117A patent/KR102943217B1/ko active Active
- 2019-11-25 US US17/297,805 patent/US12435123B2/en active Active
- 2019-11-25 MX MX2021006194A patent/MX2021006194A/es unknown
- 2019-11-25 CN CN201980079481.0A patent/CN113166232A/zh active Pending
- 2019-11-25 SG SG11202105480WA patent/SG11202105480WA/en unknown
- 2019-11-25 BR BR112021010331-7A patent/BR112021010331A2/pt unknown
- 2019-11-25 WO PCT/US2019/063024 patent/WO2020117526A1/en not_active Ceased
- 2019-11-25 CA CA3121128A patent/CA3121128A1/en active Pending
- 2019-11-25 EP EP19893181.8A patent/EP3891177A4/en active Pending
- 2019-11-25 JP JP2021530163A patent/JP2022510207A/ja active Pending
- 2019-11-25 AU AU2019392265A patent/AU2019392265A1/en active Pending
-
2021
- 2021-06-01 IL IL283607A patent/IL283607A/en unknown
-
2025
- 2025-02-06 JP JP2025018442A patent/JP2025072543A/ja active Pending